P317: Societal cost-of-illness of Inflammatory Bowel Disease has rapidly increased over the years and differs between continents: A systematic reviewECCO'21 VirtualYear: 2021
Authors: Van Linschoten, R.(1);Visser, E.(2);Niehot, C.(3);van der Woude, J.(4);Hazelzet, J.(5);van Noord, D.(1);West, R.(1);
(1)Franciscus Gasthuis & Vlietland, Gastroenterology & Hepatology, Rotterdam, The Netherlands;(2)Erasmus MC, Medical School, Rotterdam, The Netherlands;(3)Erasmus MC, Medical Library, Rotterdam, The Netherlands;(4)Erasmus MC, Gastroenterology & Hepatology, Rotterdam, The Netherlands;(5)Erasmus MC, Public Health, Rotterdam, The Netherlands
P319: Impact of biological agents on postoperative complications in inflammatory bowel disease: a multicentre study of GETECCUECCO'21 VirtualYear: 2021
Authors: García García, M.J.(1);Rivero, M.(1);Miranda-Bautista, J.(2);Bastón-Rey, I.(3);Mesonero, F.(4);Leo-Carnerero, E.(5);Casas-Deza, D.(6);Cagigas Fernández, C.(7);Martin-Cardona, A.(8);El Hajra, I.(9);Hernández-Aretxabaleta, N.(10);Pérez-Martínez, I.(11);Fuentes-Valenzuela, E.(12);Jiménez, N.(13);Rubín de Célix, C.(14);Gutiérrez, A.(15);Suárez Ferrer, C.(16);Huguet, J.M.(17);Fernández-Clotet, A.(18);González-Vivó, M.(19);Del Val, B.(20);Castro-Poceiro, J.(21);Melcarne, L.(22);Dueñas, C.(23);Izquierdo, M.(24);Monfort, D.(25);Bouhmidi, A.(26);Ramírez De la Piscina, P.(27);Romero, E.(28);Molina, G.(29);Zorrilla , J.(30);Calvino-Suárez, C.(3);Sánchez, E.(4);Nuñez, A.(5);Sierra, O.(6);Castro, B.(1);Zabana, Y.(8);González-Partida, I.(9);Chaparro, M.(14);Gisbert, J.P.(14);
(1)Hospital Universitario Marqués de Valdecilla- IDIVAL, Gastroenterology Department, Santander, Spain;(2)Hospital Universitario Gregorio Marañón- Instituto de Investigación Sanitaria Gregorio Marañón IiSGM- and Departamento de Medicina- Universidad Complutense, Gastroenterology Department, Madrid, Spain;(3)Hospital Universitario Clínico de Santiago, Gastroenterology Department, Santiago de Compostela, Spain;(4)Hospital Universitario Ramón y Cajal, Gastroenterology Department, Madrid, Spain;(5)Hospital Universitario Virgen del Rocío, Gastroenterology Department, Sevilla, Spain;(6)Hospital Universitario Miguel Servet. Instituto de Investigación Sanitaria Aragón IISA, Gastroenterology Department, Zaragoza, Spain;(7)Hospital Universitario Marqué de Valdecilla, Colorectal Unit. Department of General and Digestive Surgery, Santander, Spain;(8)Hospital Universitari Mútua Terrassa- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBERehd, Gastroenterology Department, Terrassa, Spain;(9)Hospital Universitario Puerta de Hierro, Gastroenterology Department, Majadahonda, Spain;(10)Hospital Universitario de Basurto, Gastroenterology Department-, Bilbao, Spain;(11)Hospital Universitario Central de Asturias. Instituto de Investigación Sanitaria del Principado de Asturias ISPA, Department of Gastroenterology-, Oviedo, Spain;(12)Hospital Universitario Río Hortega, Gastroenterology Department-, Valladolid, Spain;(13)Hospital General Universitario de Elche, Gastroenterology Department., Elche, Spain;(14)Hospital Universitario de La Princesa- Instituto de Investigación Sanitaria Princesa IIS-IP. Universidad Autónoma de Madrid UAM. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBERehd, Gastroenterology Department-, Madrid, Spain;(15)Hospital General de Alicante. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBERehd. Instituto de Investigación Sanitaria y Biomédica de Alicante ISABIAL, Gastroenterology Department-, Alicante, Spain;(16)Hospital Universitario La Paz, Gastroenterology Department-, Madrid, Spain;(17)Hospital General Universitario de Valencia, Gastroenterology Department-, Valencia, Spain;(18)Hospital Clinic of Barcelona, Gastroenterology Department-, Barcelona, Spain;(19)Hospital del Mar, Gastroenterology Department, Barcelona, Spain;(20)Hospital Rafael Méndez, Gastroenterology Department, Lorca, Spain;(21)Hospital Sant Joan Despí-Moisès Broggi, Gastroenterology Department-, Barcelona, Spain;(22)Hospital Universitari Parc Taulí- Sabadell- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBERehd, Gastroenterology Department-, Barcelona, Spain;(23)Hospital Universitario de Cáceres, Gastroenterology Department-, Cáceres, Spain;(24)Hospital Universitario de Cabueñes, Gastroenterology Department-, Gijón, Spain;(25)Consorcio Sanitario de Terrasa, Gastroenterology Department-, Barcelona, Spain;(26)Hospital de Santa Bárbara, Gastroenterology Department-, Puertollano, Spain;(27)Hospital Universitario Vitoria-Gastéiz, Gastroenterology Department-, Vitoria, Spain;(28)Hospital Clínico Universitario de Valencia, Gastroenterology Department-, Valencia, Spain;(29)Hospital Arquitecto Marcide, Gastroenterology Department-, Ferrol, Spain;(30)Hospital Universitario Gregorio Marañón, Department of Colorectal and Gastrointestinal Surgery, Madrid, Spain; on behalf of the Young Group of GETECCU
P320: Combined mesenchymal stromal cells and anti-cytokine therapy of perianal Crohn's diseaseECCO'21 VirtualYear: 2021
Authors: Knyazev, O.(1,2,3);Kagramanova, A.V.(1);Lishchinskaya, A.(1);Shkurko, T.(4);Li, I.(1);Parfenov, A.(1);
(1)Moscow Scientific Center named after A. S. Loginov, Department of IBD, Moscow, Russian Federation;(2)State Scientific Centre of Coloproctology named after A.N. Ryzhyh, Department of IBD, Moscow, Russian Federation;(3)Research Institute of Health Organization and Medical Management, Organization of Coloproctology, Moscow, Russian Federation;(4)Research Institute of Health Organization and Medical Management, Organization of Coloproctology, Moscow, Russian Federation
P321: Cessation of Anti-Tumour Necrosis Factor Therapy in Patients with Perianal Fistulizing Crohn’s Disease: Individual Patient Data Meta-Analysis of 323 patients from 12 studiesECCO'21 VirtualYear: 2021
Authors: Ten Bokkel Huinink, S.(1);van der Woude, J.(1);Casanova, M.J.(2);Bouguen, G.(3);Mak, J.W.Y.(4);Molnar, T.(5);Seidelin, J.(6);Aurelien, A.(7);D'Haens, G.(8);Riviere, P.(9);Guidi, L.(10);Renata, B.(5);Lin, W.C.(11);de Vries, A.(12);
(1)Erasmus Medical Center, Gastroenterology and hepatology, Amsterdam, The Netherlands;(2)Hospital Universitario de La Princesa- Instituto de Investigación Sanitaria Princesa IIS-IP- Universidad Autónoma de Madrid UAM and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD, Gastroenterology, Madrid, Spain;(3)University Hospital of Pontchaillou, Gastroenterology and Hepatology, Rennes, France;(4)Chinese University of Hong, Medicine and Therapeutics, Hong Kong, Hong Kong- China;(5)University of Szeged, First department of Medicine, Szeged, Hungary;(6)Herlev Hospital, Gastroenterology and Hepatology, Copenhagen, Denmark;(7)Henri Mondor Hospital- Assistance Publique-Hôpitaux de Paris APHP- Paris Est Creteil University UPEC, Gastroenterology, Creteil, France;(8)Amsterdam UMC- location AMC, Gastroenterology and Hepatology, Amsterdam, The Netherlands;(9)Hospitalier Universitaire, Gastroenterology and Hepatology, Bordeaux, France;(10)Università Cattolica del Sacro Cuore, Internal medicine, Rome, Italy;(11)Mackay Memorial Hospital, Gastroenterology and Hepatology, Taipei, Taiwan- Province Of China;(12)Erasmus MC, Gastroenterology and Hepatology, Rotterdam, The Netherlands
P322: Hepatitis B reactivation under biologic therapy in patients with HBsAg negative phase of chronic HBV infectionECCO'21 VirtualYear: 2021
Authors: Ergenç, I.(1);Kani, H.T.(1);Karabacak, M.(2);Cömert Özer, E.(3);Mehdiyev, S.(1);Jafarov, F.(1);Abacar, K.Y.(2);Kutluğ Ağaçkıran, S.(2);Seven Sevik, G.(2);Alibaz Öner, F.(2);İnanç, N.(2);Atagündüz, M.P.(2);Gençosmanoğlu, D.S.(3);Özen Alahdab, Y.(1);Ergun, T.(3);Direskeneli, R.H.(2);Atuğ, Ö.(1);
(1)Marmara University School of Medicine, Gastroenterology, istanbul, Turkey;(2)Marmara University School of Medicine, Rheumatology, istanbul, Turkey;(3)Marmara University School of Medicine, Dermatology, istanbul, Turkey
P323: Efficacy and safety of tofacitinib treatment for one year in Japanese patients with Ulcerative Colitis in a specialized Inflammatory Bowel Disease centerECCO'21 VirtualYear: 2021
Authors: Kojima, K.(1);Yokoyama, K.(1);Kaku, K.(1);Takashima, Y.(1);Sato, T.(1);Kawai, M.(1);Kamikozuru, K.(1);Takagawa, T.(1);Yokoyama, Y.(1);Watanabe, K.(1);
(1)Hyogo College of Medicine, Center for Inflammatory Bowel Disease- Division of Internal Medicine, Nishinomiya, Japan
P324: Predictors of corticosteroid-free remission after initiation of ustekinumab for ulcerative colitis: a real-world, multicenter cohort study in the United StatesECCO'21 VirtualYear: 2021
Authors: Dalal, R.(1);Esckilsen, S.(2);Barnes, E.(3);McClure, E.(1);Goodrick, H.(1);Allegretti, J.(1);
(1)Brigham and Women's Hospital- Harvard Medical School, Gastroenterology- Hepatology and Endoscopy, Boston, United States;(2)University of North Carolina at Chapel Hill, Medicine, Chapel Hill- NC, United States;(3)University of North Carolina at Chapel Hill, Gastroenterology and Hepatology, Chapel Hill- NC, United States
P325: Real-World Effectiveness And Safety Of Ustekinumab In Patients With Ulcerative Colitis: A Multi-Centre StudyECCO'21 VirtualYear: 2021
Authors: Parakkal, D.(1);Johnson, A.(2);Fenster, M.(3);Ramos, G.(2);Zulqarnain, M.(4);Ullman, T.(3);Huang, L.(1);Gutierrez, A.(1);Bruss, A.(4);Ungaro, R.(5);Cohen, B.(6);Gaurav, S.(7);Anish, P.(8);Sasankan, P.(6);Costable, N.(5);Pekow, J.(9);Wang, W.(9);Rubin, D.(9);Ciorba, M.(1);Beniwal-Patel, P.(4);Loftus, E.(2);Yarur, A.(4);
(1)Washington University, University of Washington, St. Louis, United States;(2)Mayo Clinic, Gastroenterology, Rochester, United States;(3)Montefiore Medical Center, Gastroenterology, New York, United States;(4)Medical College of Wisconsin, Department of Gastroenterology, Milwaukee, United States;(5)The Mount Sinai Hospital, Gastroenterology, New York, United States;(6)Cleveland Clinic, Gastroenterology, Cleveland, United States;(7)Cedars Sinai Medical Center, Gastroenterology, Los Angeles, United States;(8)US Army Brooke Army Medical Center, Gastroenterology, Fort Sam Houston, United States;(9)University of Chicago Medicine, Gastroenterology, Chicago, United States
P326: An exploratory analysis of the impact of COVID-19 on colonoscopy procedures and new biologic treatment initiation among patients with Inflammatory Bowel Disease in the United StatesECCO'21 VirtualYear: 2021
Authors: Ungaro, R.(1);Chou, B.(2);Mo, J.(3);Ursos, L.(4);Twardowski, R.(5);Candela, N.(6);Colombel, J.F.(1);
(1)The Mount Sinai Hospital- Feinstein IBD Clinical Center, Gastroenterology, New York, United States;(2)Takeda Pharmaceuticals USA- Inc., Analytics and Data Science, Lexington, United States;(3)Takeda Pharmaceuticals USA- Inc., Analytics, Lexington, United States;(4)Takeda Pharmaceuticals USA- Inc., Speciality Medical, Lexington, United States;(5)Takeda Pharmaceuticals USA- Inc., Data and Market Analytics and Insights, Lexington, United States;(6)Takeda Pharmaceuticals USA- Inc., US Medical, Lexington, United States
P327: Long-term effectiveness of ustekinumab in refractory Crohn's disease: an Italian multicenter real-life studyECCO'21 VirtualYear: 2021
Authors: Scribano, M.L.(1);Aratari, A.(2);Neri, B.(3);Bezzio, C.(4);Balestrieri, P.(5);Falasco, G.(1);Camastra, C.(1);Pantanella, P.(1);Monterubbianesi, R.(1);Tullio, A.(5);Saibeni, S.(4);Papi, C.(2);Biancone, L.(3);Cosintino, R.(1);Faggiani, R.(1);
(1)Gastroenterology Unit, Azienda Ospedaliera San Camillo-Forlanini, Rome, Italy;(2)IBD Unit, San Filippo Neri Hospital, Rome, Italy;(3)Department of Systems Medicine- Gastroenterology Unit, University Tor Vergata of Rome, Rome, Italy;(4)Gastroenterology Unit, Rho Hospital- ASST Rhodense, Rho, Italy;(5)Gastroenterology Unit, Campus Bio Medico University, Rome, Italy
P328: Ustekinumab is an effective and safe therapy in anti-TNF refractory Crohn’s Disease: a two year real-life observational study from SpainECCO'21 VirtualYear: 2021
Authors: Rueda Sanchez, J.(1);Cabello Ramirez, M.(1);Camara Baena, S.(1);Keco Huerga, A.(1);Garcia de la Borbolla Serres, J.(1);Castro Fernandez, M.(1);Grande Santamaria, L.(1);
(1)Virgen de Valme Universitary Hospital, CGU Gastroenterology, Sevilla, Spain
P329: Comparative Assessment of Adalimumab Trough Levels between Point-of-Care Testing and current Standard of Care (enzyme linked immunosorbent assay) in patients with Inflammatory Bowel DiseaseECCO'21 VirtualYear: 2021
Authors: Marsilio, I.(1);MANIERO, D.(1);Lorenzon, G.(1);Rigo, A.(1);Cardin, R.(1);Facchin, S.(1);Barberio, B.(1);D'Incà, R.(1);Zingone, F.(1);Bahur, B.(2);Bray, K.B.(3);Savarino, E.V.(1);
(1)Padua University Hospital, Department of Surgery- Oncology and Gastroenterology, Padua, Italy;(2)ProciseDx, Department of Clinical Trials, San Diego, United States;(3)ProciseDx, Department of Clinical Development and Medical Affairs, San Diego, United States
P330: Long-term outcomes following a switch from originator adalimumab to the biosimilar SB5 (Imraldi) in IBDECCO'21 VirtualYear: 2021
Authors: Derikx, L.(1,2);Dolby, H.(2);Plevris, N.(2);Lucaciu , L.(2);Rees, C.(2);Lyons, M.(2);Siakavellas, S.(2);Constantine-Cooke, N.(3);Noble, C.(2);O’Hare, C.(2);Merchant, L.(2);Arnott, I.(2);Jones, G.R.(2,4);Lees, C.(2,5);
(1)Radboud University Nijmegen Medical Centre, Inflammatory Bowel Disease Centre- Department of Gastroenterology and Hepatology- Route 455, Nijmegen, The Netherlands;(2)Western General Hospital, Edinburgh IBD Unit, Edinburgh, United Kingdom;(3)University of Edinburgh- Western General Hospital, MRC Human Genetics Unit- Institute of Genetics and Molecular Medicine-, Edinburgh, United Kingdom;(4)University of Edinburgh, Centre for Inflammation Research- The Queen's Medical Research Institute, Edinburgh, United Kingdom;(5)University of Edinburgh- Western General Hospital, Centre for Genomics and Experimental Medicine- Institute of Genetics and Molecular Medicine, Edinburgh, United Kingdom
P331: The safety of tioguanine exposure during pregnancy: a case series of seventy-three pregnanciesECCO'21 VirtualYear: 2021
Authors: Crouwel, F.(1);Simsek, M.(1);De Boer, M.A.(2);Mulder, C.J.J.(1);Buiter, H.J.C.(3);De Boer, N.K.(1);
(1)Amsterdam UMC- location VUmc, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(2)Amsterdam UMC- location VUmc, Department of Obstetrics and Gynaecology, Amsterdam, The Netherlands;(3)Amsterdam UMC- location VUmc, Department of Radiology and Nuclear Medicine, Amsterdam, The Netherlands; On behalf of the tioguanine pregnancy study group and the Dutch Initiative on Crohn and Colitis (ICC)
P332: Population pharmacokinetics of ozanimod and active metabolite CC112273 in patients with ulcerative colitisECCO'21 VirtualYear: 2021
Authors: Shen, J.(1);Tatosian, D.(1);Sid-Otmane, L.(2);Teuscher, N.(3);Chen, L.(1);Zhang, P.(1);Tirucherai, G.S.(1);Chitakara, D.(1);Marta, C.(1);
(1)Bristol Myers Squibb, Research and Development, Princeton, United States;(2)Certara USA- Inc., Integrated Drug Development, Montréal, Canada;(3)Certara USA- Inc., Integrated Drug Development, Raleigh, United States
P333: Endoscopic severity and CRP predict failure of medical rescue therapy in patients with acute severe ulcerative colitisECCO'21 VirtualYear: 2021
Authors: Kakkadasam Ramaswamy, P.(1);Subhaharan, D.(1);Willmann, L.(1);Edwards, J.(1);Shukla, D.(1);Bhullar, M.(1);Moattar, H.(1);Dorrington, A.(1);Ishaq, N.(1);McIvor, C.(2);Mohsen, W.(1);
(1)Gold Coast University Hospital, Department of Digestive Health, Southport, Australia;(2)Logan Hospital, Department of Gastroenterology, Meadowbrook, Australia
P334: Tofacitinib for the treatment of Ulcerative Colitis: Analysis of malignancy rates from the Ulcerative Colitis clinical programmeECCO'21 VirtualYear: 2021
Authors: Ungaro, R.C.(1);Ciorba, M.A.(2);Rogler, G.(3);Sharara, A.I.(4);Sunna, N.(5);Connelly, S.B.(6);Mundayat, R.(7);Lawendy, N.(6);Panés, J.(8);
(1)Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York- New York, United States;(2)Division of Gastroenterology, Washington University in St. Louis, St. Louis- Missouri, United States;(3)Department of Gastroenterology and Hepatology, University of Zürich, Zürich, Switzerland;(4)Division of Gastroenterology, American University of Beirut Medical Center, Beirut, Lebanon;(5)-, Pfizer Inc, Amman, Jordan;(6)Pfizer Inc, Collegeville, Pennsylvania, United States;(7)Pfizer Inc, New York, New York, United States;(8)Department of Gastroenterology, Hospital Clínic de Barcelona- IDIBAPS- CIBERehd, Barcelona, Spain
P335: Real-life effectiveness and safety of tofacitinib treatment in patients with ulcerative colitis: A KASID multicenter cohort studyECCO'21 VirtualYear: 2021
Authors: Oh, K.(1);Hong, S.N.(2);Kim, E.S.(3);Na, S.Y.(4);Kang, S.B.(5);Koh, S.J.(6);Bang, K.B.(7);Jung, S.A.(8);Kim, K.O.(9);Choi, C.H.(10);Ye, B.D.(11);
(1)University of Ulsan College of Medicine- Asan Medical Center, Gastroenterology, Seoul, Korea- Republic Of;(2)Samsung Medical Center- Sungkyunkwan University School of Medicine, Medicine, Seoul, Korea- Republic Of;(3)Kyungpook National University School of Medicine, Internal Medicine, Daegu, Korea- Republic Of;(4)College of Medicine- Incheon St. Mary's Hospital- The Catholic University of Korea, Internal Medicine, Incheon, Korea- Republic Of;(5)College of Medicine- Daejeon St. Mary's Hospital- The Catholic University of Korea, Internal Medicine, Daejeon, Korea- Republic Of;(6)Seoul National University College of Medicine, Internal Medicine and Liver Research Institute, Seoul, Korea- Republic Of;(7)Dankook University College of Medicine, Internal Medicine, Cheonan, Korea- Republic Of;(8)Ewha Womans University School of Medicine, Internal Medicine, Seoul, Korea- Republic Of;(9)Yeungnam University College of Medicine, Internal Medicine, Daegu, Korea- Republic Of;(10)Chung-Ang University College of Medicine, Internal Medicine, Seoul, Korea- Republic Of;(11)University of Ulsan College of Medicine- Asan Medical Center, Gastroenterology and Inflammatory Bowel Disease Center, Seoul, Korea- Republic Of; IBD Research Group of the Korean Association for the Study of Intestinal Diseases
P336: Association between the prior duration of remission and efficacy outcomes in patients with Ulcerative Colitis treated with tofacitinib 10 mg twice daily who were in stable remission and either dose-reduced to tofacitinib 5 mg twice daily or remained on 10 mg twice daily: 6-month data from the double-blind, randomised RIVETING studyECCO'21 VirtualYear: 2021
Authors: Dubinsky, M.C.(1);D’Haens, G.R.(2);Sandborn, W.J.(3);Ng, S.C.(4);Panés, J.(5);Su, C.(6);Lawendy, N.(6);Lazariciu, I.(7);Gardiner, S.(7);Mundayat, R.(7);Kulisek, N.(6);Modesto, I.(7);Torres, J.(8);
(1)Icahn School of Medicine at Mount Sinai, New York, New York, United States;(2)Department of Gastroenterology, Amsterdam University Medical Centres, Amsterdam, The Netherlands;(3)Division of Gastroenterology, University of California, San Diego- La Jolla- California, United States;(4)Institute of Digestive Disease- Department of Medicine and Therapeutics, LKS Institute of Health Science- Chinese University of Hong Kong, Hong Kong, Hong Kong- China;(5)Department of Gastroenterology, Hospital Clínic de Barcelona- IDIBAPS- CIBERehd, Barcelona, Spain;(6)Pfizer Inc, Collegeville, Pennsylvania, United States;(7)Pfizer Inc, New York, New York, United States;(8)Surgical Department- Gastroenterology Division, Hospital Beatriz Ângelo- Loures, and Faculdade de Medicina- Universidade de Lisboa- Lisbon, Portugal
